AR063470A1 - Terapia combinada - Google Patents
Terapia combinadaInfo
- Publication number
- AR063470A1 AR063470A1 ARP070103423A ARP070103423A AR063470A1 AR 063470 A1 AR063470 A1 AR 063470A1 AR P070103423 A ARP070103423 A AR P070103423A AR P070103423 A ARP070103423 A AR P070103423A AR 063470 A1 AR063470 A1 AR 063470A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- effective amount
- combination
- vla
- radiotherapy
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 2
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- MNQBPRHHZPXCKZ-ZDCRTTOTSA-N (2s)-2-[[(2s)-1-(3,5-dichlorophenyl)sulfonylpyrrolidine-2-carbonyl]amino]-4-[[(2s)-4-methyl-2-[methyl-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoyl]amino]butanoic acid Chemical compound CN([C@@H](CC(C)C)C(=O)NCC[C@H](NC(=O)[C@H]1N(CCC1)S(=O)(=O)C=1C=C(Cl)C=C(Cl)C=1)C(O)=O)C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C MNQBPRHHZPXCKZ-ZDCRTTOTSA-N 0.000 abstract 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 230000001483 mobilizing effect Effects 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 abstract 1
- 229960002169 plerixafor Drugs 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83529006P | 2006-08-02 | 2006-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063470A1 true AR063470A1 (es) | 2009-01-28 |
Family
ID=38997866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103423A AR063470A1 (es) | 2006-08-02 | 2007-08-02 | Terapia combinada |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100003224A1 (https=) |
| EP (1) | EP2068868A2 (https=) |
| JP (1) | JP2009545620A (https=) |
| CN (1) | CN101495115A (https=) |
| AR (1) | AR063470A1 (https=) |
| AU (1) | AU2007281090A1 (https=) |
| BR (1) | BRPI0714799A2 (https=) |
| CA (1) | CA2659463A1 (https=) |
| IL (1) | IL196556A0 (https=) |
| MX (1) | MX2009001272A (https=) |
| RU (1) | RU2009107030A (https=) |
| WO (1) | WO2008017025A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004020462A1 (ja) | 2002-08-27 | 2004-03-11 | Fujii, Nobutaka | Ｃｘｃｒ４拮抗薬およびその用途 |
| CA2673719C (en) * | 2006-12-21 | 2018-07-24 | Biokine Therapeutics Ltd. | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
| US9427456B2 (en) | 2009-06-14 | 2016-08-30 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
| WO2012034194A1 (en) * | 2010-09-17 | 2012-03-22 | Antisense Therapeutics Ltd | Method for mobilizing stem and/or progenitor cells |
| US9682078B2 (en) | 2011-03-18 | 2017-06-20 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| RU2638802C2 (ru) | 2011-05-16 | 2017-12-15 | Джензим Корпорейшн | Применение антагонистов cxcr4 |
| WO2012174522A1 (en) * | 2011-06-16 | 2012-12-20 | Children's Medical Center Corporation | Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment |
| US9439942B2 (en) | 2012-04-24 | 2016-09-13 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
| SG11201704756YA (en) * | 2014-12-12 | 2017-07-28 | Commw Scient Ind Res Org | Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist |
| IL274572B2 (en) | 2015-07-16 | 2024-01-01 | Biolinerx Ltd | Compositions and methods for treating cancer |
| CN109310733A (zh) | 2016-02-23 | 2019-02-05 | 百欧林纳克斯有限公司 | 治疗急性骨髓性白血病的方法 |
| JP7034085B2 (ja) * | 2016-04-08 | 2022-03-11 | サイロス ファーマシューティカルズ， インコーポレイテッド | Ａｍｌ及びｍｄｓの治療のためのｒａｒａアゴニスト |
| WO2018085574A2 (en) * | 2016-11-02 | 2018-05-11 | Washington University | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof |
| TWI734027B (zh) * | 2017-09-18 | 2021-07-21 | 泰宗生物科技股份有限公司 | 用於治療癌症之組合物 |
| CN111712262A (zh) * | 2017-12-06 | 2020-09-25 | 美真达治疗公司 | 用于动员造血干细胞和祖细胞的给药方案 |
| US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| DE69433301T2 (de) * | 1993-06-08 | 2004-09-09 | Smithkline Beecham Corp. | Methoden zur erhöhung der biologischen aktivität von chemokinen |
| US6447766B1 (en) * | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
| US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| ATE180843T1 (de) * | 1994-08-19 | 1999-06-15 | Akzo Nobel Nv | Zelluloselösungen und hieraus hergestellte produkte |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US5968546A (en) * | 1997-05-16 | 1999-10-19 | Baur; Marcus | Keratinocyte culture from precursor cells |
| HUP0102255A3 (en) * | 1998-05-28 | 2001-12-28 | Biogen Idec Ma Inc Cambridge | Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| US6750348B1 (en) * | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| GEP20053477B (en) * | 1999-08-13 | 2005-03-25 | Biogen Inc | Cell Adhesion Inhibitors and Pharmaceutical Compositions Containing Them |
| DE60042030D1 (de) * | 1999-12-17 | 2009-05-28 | Genzyme Corp | Chemokinrezeptor-bindende heterocyclische verbindungen |
| US6835731B2 (en) * | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| PT1317451E (pt) * | 2000-09-15 | 2006-12-29 | Anormed Inc | Compostos heterocíclicos que se ligam a receptores de quimioquinas |
| CA2419224A1 (en) * | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| AU2002211393B2 (en) * | 2000-09-29 | 2007-06-28 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
| EP1613613B1 (en) * | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| AU2004232361A1 (en) * | 2003-04-22 | 2004-11-04 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| EP1708703A4 (en) * | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
| CN1930127B (zh) * | 2004-03-15 | 2012-11-21 | 阿诺麦德股份有限公司 | 用于合成cxcr4拮抗剂的方法 |
| JP2008509928A (ja) * | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
| US7825088B2 (en) * | 2005-04-25 | 2010-11-02 | The Cbr Institute For Biomedical Research, Inc. | Methods for the treatment of multiple myeloma |
-
2007
- 2007-08-02 AU AU2007281090A patent/AU2007281090A1/en not_active Abandoned
- 2007-08-02 US US12/375,987 patent/US20100003224A1/en not_active Abandoned
- 2007-08-02 BR BRPI0714799-6A patent/BRPI0714799A2/pt not_active Application Discontinuation
- 2007-08-02 AR ARP070103423A patent/AR063470A1/es not_active Application Discontinuation
- 2007-08-02 WO PCT/US2007/075064 patent/WO2008017025A2/en not_active Ceased
- 2007-08-02 CN CNA200780028588XA patent/CN101495115A/zh active Pending
- 2007-08-02 EP EP07813695A patent/EP2068868A2/en not_active Withdrawn
- 2007-08-02 CA CA002659463A patent/CA2659463A1/en not_active Abandoned
- 2007-08-02 JP JP2009523051A patent/JP2009545620A/ja not_active Withdrawn
- 2007-08-02 MX MX2009001272A patent/MX2009001272A/es unknown
- 2007-08-02 RU RU2009107030/15A patent/RU2009107030A/ru not_active Application Discontinuation
-
2009
- 2009-01-15 IL IL196556A patent/IL196556A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101495115A (zh) | 2009-07-29 |
| EP2068868A2 (en) | 2009-06-17 |
| WO2008017025A2 (en) | 2008-02-07 |
| WO2008017025A3 (en) | 2008-10-09 |
| JP2009545620A (ja) | 2009-12-24 |
| BRPI0714799A2 (pt) | 2013-05-21 |
| MX2009001272A (es) | 2009-02-11 |
| AU2007281090A1 (en) | 2008-02-07 |
| US20100003224A1 (en) | 2010-01-07 |
| IL196556A0 (en) | 2009-11-18 |
| RU2009107030A (ru) | 2010-09-10 |
| CA2659463A1 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063470A1 (es) | Terapia combinada | |
| AR062271A1 (es) | Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| ECSP10010589A (es) | Farmaco contra el cancer de higado | |
| CU20070203A7 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
| MX339658B (es) | Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa. | |
| UY28081A1 (es) | Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular | |
| AR049955A1 (es) | Composiciones y metodos para el tratamiento de trastornos metabolicos | |
| MX2009008022A (es) | Metodos y composiciones para tratar neuropatias. | |
| AR072947A1 (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad, celular dependiente de anticuerpos (ccda) aumentada, composicion farmaceutica, anticuerpo anti-cd20 de tipo ii | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| AR060089A1 (es) | Tratamiento del dolor | |
| WO2011041478A8 (en) | Hematopoietic stem cells for use in the treatment of a kidney injury | |
| CO6311006A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas | |
| RU2013132566A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
| JP2009545620A5 (https=) | ||
| CO5670356A2 (es) | Programa de dosificaicon para un nuevo agente anticanceroso | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| MX2023003942A (es) | Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r. | |
| MX361816B (es) | Suministro intraventricular lento. | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| RU2008148597A (ru) | Фармацевтические комбинации | |
| MX2022005664A (es) | Virus de vaccinia ankara modificados (mva) recombinantes para administración intratumoral y/o intravenosa para tratamiento de cáncer. | |
| MY158929A (en) | Pharmaceutical combination | |
| MX2024010506A (es) | Composiciones y metodos para la reduccion de celulas madre hematopoyeticas enfermas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |